journal article·2024-10

A Multifunctional Rocket‐Like Microneedle System with Thrusters for Self‐Promoted Deep Drug Penetration and Combination Treatment in Melanoma

Xiaohui Pan, Yixin Kang, Shuyao Zhou, Tingting Zhang, Yaxin Zheng, Qiling Jin, Wenying Zhong, Keming Xu

Advanced Functional Materials· Volume 34· Issue 40
Publisher page

Abstract

Abstract Photodynamic therapy (PDT) proves highly effective in addressing melanoma, and its synergy with targeted therapy offers a promising avenue in tumor treatment. However, the therapeutic outcome is largely impeded by the challenge of current photosensitizers and targeted drugs in reaching deep tumor tissues. Herein, a dually‐layered “microneedle rocket” termed PcNP/TRA‐HA‐Tyr/CLG‐MN is designed. The upper layer of the microneedle (MN) is composed of photodynamically active mesoporous silica nanoparticles, featuring photosensitizers covalently bonded to them. Within the mesopores of these nanoparticles lies trametinib (TRA), a compound that specifically targets the hyperactive MEK pathway present in melanoma cells. The lower layer is composed of an enzyme‐mediated hyaluronic acid‐tyramine hydrogel (HA‐Tyr/CLG) with collagenase (CLG), serving as rocket thrusters for remodeling the extracellular matrix (ECM) in tumor microenvironment. Among the three types of MNs prepared, the PcNP/TRA‐HA‐Tyr(II)/CLG‐MN exhibits the deepest penetration in tumor tissues and the longest retention time in vivo. Notably, the administrations of PcNP/TRA‐HA‐Tyr(II)/CLG‐MN alongside light irradiation significantly suppress the growth of A375‐xenografted tumors in mice. Together, the strategy of combining mesoporous silica nanoparticles, enzymatically cross‐linked hydrogels and CLG‐mediated ECM remodeling enables deep drug penetration and efficacious combination treatment against melanoma, showcasing significant potential in the realm of cancer nanomedicine.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Advancements in Transdermal Drug Delivery · Immunotherapy and Immune Responses · Photodynamic Therapy Research Studies

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Chemistry China Pharmaceutical University Nanjing 210009 P. R. China

Key Laboratory of Biomedical Functional Materials China Pharmaceutical University Nanjing 210009 P. R. China

Key Laboratory of Drug Quality Control and Pharmacovigilance China Pharmaceutical University Nanjing 210009 P. R. China

Funding

National Natural Science Foundation of China

References (32)

Show source-provided references
1. Davids L. M. · Cancer Treat. Rev. · 2011 · 37 · 465
2. 10.3322/caac.2011410.3322/caac.20114 ↗
3. 10.1002/advs.20170011310.1002/advs.201700113 ↗
4. 10.1158/2159-8290.CD-17-060710.1158/2159-8290.CD-17-0607 ↗
5. 10.1002/adma.20180820010.1002/adma.201808200 ↗
6. 10.1016/j.bioactmat.2021.04.00410.1016/j.bioactmat.2021.04.004 ↗
7. 10.1021/acsnano.8b0300710.1021/acsnano.8b03007 ↗
8. 10.1002/adfm.20180184010.1002/adfm.201801840 ↗
9. 10.1016/j.mser.2016.03.00110.1016/j.mser.2016.03.001 ↗
10. 10.1002/adma.20150602510.1002/adma.201506025 ↗
11. 10.1002/sstr.20200009710.1002/sstr.202000097 ↗
12. Zhang X. X. · Theranostics · 2020 · 2020
13. 10.1016/j.bioactmat.2023.04.00310.1016/j.bioactmat.2023.04.003 ↗
14. 10.1016/j.addr.2018.01.01510.1016/j.addr.2018.01.015 ↗
15. 10.1039/C7LC00016B10.1039/C7LC00016B ↗
16. 10.1016/j.jconrel.2013.01.00810.1016/j.jconrel.2013.01.008 ↗
17. 10.1016/j.actbio.2015.06.02610.1016/j.actbio.2015.06.026 ↗
18. 10.1016/j.jconrel.2015.08.01510.1016/j.jconrel.2015.08.015 ↗
19. 10.1007/s12274-022-4826-010.1007/s12274-022-4826-0 ↗
20. 10.7150/thno.3999510.7150/thno.39995 ↗
21. 10.1073/pnas.220926012010.1073/pnas.2209260120 ↗
22. 10.1016/j.cis.2024.10312410.1016/j.cis.2024.103124 ↗
23. 10.1002/adma.20190674510.1002/adma.201906745 ↗
24. 10.1021/acsami.0c0302210.1021/acsami.0c03022 ↗
25. 10.1002/adfm.20200754410.1002/adfm.202007544 ↗
26. 10.1038/nature0076610.1038/nature00766 ↗
27. 10.1016/S0140-6736(15)60898-410.1016/S0140-6736(15)60898-4 ↗
28. 10.1038/s41591-019-0448-910.1038/s41591-019-0448-9 ↗
29. 10.1002/adhm.20200014710.1002/adhm.202000147 ↗
30. 10.1016/j.actbio.2020.07.02710.1016/j.actbio.2020.07.027 ↗
31. 10.1021/cm201853210.1021/cm2018532 ↗
32. 10.1002/adfm.20190263410.1002/adfm.201902634 ↗